- Home
- AMOD vs RLMD Comparison
AMOD vs RLMD Comparison
Compare AMOD & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMOD
- RLMD
- Stock Information
- Founded
- AMOD 2014
- RLMD 2004
- Country
- AMOD United States
- RLMD United States
- Employees
- AMOD N/A
- RLMD N/A
- Industry
- AMOD
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- AMOD
- RLMD Health Care
- Exchange
- AMOD NYSE
- RLMD Nasdaq
- Market Cap
- AMOD 18.7M
- RLMD 22.0M
- IPO Year
- AMOD N/A
- RLMD N/A
- Fundamental
- Price
- AMOD $1.16
- RLMD $0.63
- Analyst Decision
- AMOD
- RLMD Buy
- Analyst Count
- AMOD 0
- RLMD 3
- Target Price
- AMOD N/A
- RLMD $5.00
- AVG Volume (30 Days)
- AMOD 198.6K
- RLMD 431.8K
- Earning Date
- AMOD 08-15-2025
- RLMD 08-06-2025
- Dividend Yield
- AMOD N/A
- RLMD N/A
- EPS Growth
- AMOD N/A
- RLMD N/A
- EPS
- AMOD 0.12
- RLMD N/A
- Revenue
- AMOD N/A
- RLMD N/A
- Revenue This Year
- AMOD N/A
- RLMD N/A
- Revenue Next Year
- AMOD N/A
- RLMD N/A
- P/E Ratio
- AMOD $9.59
- RLMD N/A
- Revenue Growth
- AMOD N/A
- RLMD N/A
- 52 Week Low
- AMOD $1.01
- RLMD $0.24
- 52 Week High
- AMOD $13.49
- RLMD $4.47
- Technical
- Relative Strength Index (RSI)
- AMOD N/A
- RLMD 51.09
- Support Level
- AMOD N/A
- RLMD $0.59
- Resistance Level
- AMOD N/A
- RLMD $0.74
- Average True Range (ATR)
- AMOD 0.00
- RLMD 0.07
- MACD
- AMOD 0.00
- RLMD -0.02
- Stochastic Oscillator
- AMOD 0.00
- RLMD 45.65
About AMOD ALPHA MODUS HOLDINGS INC
Alpha Modus Holdings Inc is a technology company with a core focus on artificial intelligence in retail. It is engaged in creating, developing, and licensing data-driven technologies to enhance consumers' in-store digital experience at the point of decision.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.